annual meeting program - American Society of Clinical Oncology

Sunday, June 6, 2010
Brd. 34B Docetaxel-carboplatin chemotherapy combined with cetuximab in patients
with locally advanced or metastasized non-small cell lung cancer (NSCLC):
results of the nonrandomized phase II study TaxErb. (Abstract #7546)
J. R. Fischer, F. Griesinger, T. Fink, E. Buchholz, T. Salm, A. Marseille, M. Wolf
Brd. 34C A multicenter phase II study of sorafenib in combination with erlotinib in
patients with advanced non-small cell lung cancer (NSCLC). (Abstract #7547)
B. Cho, S. Kim, D. S. Heo, S. Kang, H. Kim, D. Lee, D. Kim, M. Jung, J. Choi,
J. Kim
Brd. 35A Patient selection for cetuximab in NSCLC: A systematic review of candidate
predictive biomarkers. (Abstract #7548)
C. Harbison, C. Stroh, T. J. Lynch, D. R. Gandara, K. J. O’Byrne, R. Pirker,
S. Maier, I. Celik, M. R. Weber, S. Khambata-Ford
Brd. 35B Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) with
EGFR in-frame deletions of exon 19 according to the size of the deletion.
(Abstract #7549)
M. Taron, C. Queralt, C. Mayo, I. de Aguirre, A. Gasco, A. Insa, R. Palmero,
C. Camps, J. Sanchez, R. Rosell
Brd. 35C Association of epithelial mesenchymal transition (EMT) markers and
outcome measures in advanced non-small cell lung cancer (NSCLC) patients
treated with erlotinib. (Abstract #7550)
N. B. Shah, M. J. Fidler, K. K. Walters, E. Braun, S. Basu, H. Harasty, J. Coon,
M. Pool, T. A. Hensing, P. D. Bonomi
Brd. 35D Randomized phase II study of gefitinib versus erlotinib in patients with
advanced non-small cell lung cancer who failed previous chemotherapy.
(Abstract #7551)
J. Ahn, S. Kim, M. Ahn, J. Lee, J. Uhm, J. Sun, K. Park, Y. Park
Brd. 35E The association between PTEN expression and survival in patients (pts) with
advanced non-small cell lung cancer (NSCLC) treated with erlotinib.
(Abstract #7552)
T. A. Hensing, M. J. Fidler, F. Wong, A. Polish, W. Watkin, S. Basu, K. A. Kaiser-
Walters, M. Pool, J. Coon, P. Bonomi
Brd. 35F Insulin-like growth factor binding proteins related to progression-free
survival (PFS) and overall survival (OS) in advanced non-small cell lung
cancer (NSCLC) patients treated with chemotherapy. (Abstract #7553)
R. Karmali, M. J. Fidler, I. Cela, G. Olmsted, O. Rouhi, S. Basu, K. K. Walters,
J. Coon, P. Bonomi, J. A. Borgia
Brd. 35G SNaPshot multigene assay to detect mechanisms of acquired resistance to
EGFR tyrosine kinase inhibitors (TKIs). (Abstract #7554)
B. A. Waltman, D. Dias-Santagata, A. K. Cosper, M. Mino-Kenudson, D. R. Borger,
P. Fidias, A. T. Shaw, A. J. Iafrate, J. A. Engelman, L. V. Sequist
Brd. 35H Expression of MET, IGF-1R, IL-6/gp130, and AXL in erlotinib-treated nonsmall
cell lung cancer (NSCLC) patients (p) with EGFR mutations.
(Abstract #7555)
C. Costa, A. Gimenez Capitan, C. Mayo, S. Simonetti, M. Majem, D. Isla,
S. Benlloch, M. Taron, J. Sanchez, R. Rosell
Brd. 36A First-cycle rash as a clinical marker in patients with advanced non-small cell
lung cancer (NSCLC) receiving first-line chemotherapy (CT) plus cetuximab:
Efficacy by histology. (Abstract #7556)
K. J. O’Byrne, J. Von Pawel, I. Vynnychenko, P. Zatloukal, F. De Marinis,
W. E. Eberhardt, L. G. Paz-Ares, K. Schumacher, U. Gatzemeier, R. Pirker
Brd. 36B Phase II trial of cetuximab and erlotinib in patients with lung adenocarcinoma
and acquired resistance to erlotinib. (Abstract #7557)
G. J. Riely, Y. Y. Janjigian, C. G. Azzoli, M. Pietanza, L. M. Krug, N. A. Rizvi,
M. G. Kris, V. A. Miller, W. Pao, M. S. Ginsberg
215
SUNDAY